TransCode Therapeutics raises $1.21M in registered direct offering of 5M shares at $0.242/share

Transcode Therapeutics, Inc.

Sold 5,000,000 shares of common stock at $0.242 per share, gross proceeds of $1.21 million.
Offering closed on December 4, 2023; H.C. Wainwright & Co. acted as exclusive placement agent.
Placement agent received warrants to purchase 300,000 shares at $0.3025 per share, exercisable for 5 years.
Net proceeds will fund clinical trials for lead candidate TTX-MC138 and for working capital.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Transcode Therapeutics, Inc. entered into Securities Purchase Agreement with institutional investors named therein valued at $1.21 million (effective 2023-11-30).

Action: entry
Agreement: equity purchase
Counterparty: institutional investors named therein
Value: $1.21 million
Effective: 2023-11-30

Exact text from the filing

On November 30, 2023, TransCode Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with institutional investors named therein (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “Offering”), an aggregate of 5,000,000 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at an offering price of $0.242 per share of Common Stock.

View on SEC.gov

119 material agreements filed in the last 30 days. Browse all material agreements →

Transcode Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-123274

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.